WallStSmart

Humana Inc (HUM)vsOscar Health Inc (OSCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Humana Inc generates 1008% more annual revenue ($129.66B vs $11.70B). HUM leads profitability with a 0.9% profit margin vs -3.8%. HUM earns a higher WallStSmart Score of 58/100 (C).

HUM

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 4.0Value: 7.3Quality: 8.5
Piotroski: 4/9Altman Z: 4.37

OSCR

Hold

45

out of 100

Grade: D

Growth: 9.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HUMSignificantly Overvalued (-162.4%)

Margin of Safety

-162.4%

Fair Value

$66.84

Current Price

$174.24

$107.40 premium

UndervaluedFair: $66.84Overvalued

Intrinsic value data unavailable for OSCR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HUM4 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
4.3710/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.998/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

OSCR2 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.3%8/10

17.3% revenue growth

EPS GrowthGrowth
47.2%8/10

Earnings expanding 47.2% YoY

Areas to Watch

HUM4 concerns · Avg: 2.5/10
Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Profit MarginProfitability
0.9%3/10

0.9% margin — thin

EPS GrowthGrowth
-59.3%2/10

Earnings declined 59.3%

Free Cash FlowQuality
$-1.85B2/10

Negative free cash flow — burning cash

OSCR4 concerns · Avg: 2.0/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-44.4%2/10

ROE of -44.4% — below average capital efficiency

Altman Z-ScoreHealth
0.962/10

Distress zone — elevated risk

Profit MarginProfitability
-3.8%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : HUM

The strongest argument for HUM centers on Price/Book, Altman Z-Score, PEG Ratio. Revenue growth of 11.3% demonstrates continued momentum. PEG of 0.99 suggests the stock is reasonably priced for its growth.

Bull Case : OSCR

The strongest argument for OSCR centers on Revenue Growth, EPS Growth. Revenue growth of 17.3% demonstrates continued momentum.

Bear Case : HUM

The primary concerns for HUM are Return on Equity, Profit Margin, EPS Growth. Thin 0.9% margins leave little buffer for downturns.

Bear Case : OSCR

The primary concerns for OSCR are Piotroski F-Score, Return on Equity, Altman Z-Score.

Key Dynamics to Monitor

HUM profiles as a value stock while OSCR is a growth play — different risk/reward profiles.

OSCR carries more volatility with a beta of 1.90 — expect wider price swings.

OSCR is growing revenue faster at 17.3% — sustainability is the question.

OSCR generates stronger free cash flow (663M), providing more financial flexibility.

Bottom Line

HUM scores higher overall (58/100 vs 45/100) and 11.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Humana Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Humana Inc. is a for-profit American health insurance company based in Louisville, Kentucky.

Visit Website →

Oscar Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Oscar Health, Inc. offers health insurance products and services to individuals, families, and businesses in the United States. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?